Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics
|
July 24, 2012
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
James A Rogers, Daniel Polhamus, William R Gillespie, et al.
BMJ Open
|
March 8, 2013
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
Jorge Luiz Gross, James Rogers, Daniel Polhamus, et al.
Expert Review of Clinical Pharmacology
|
March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis
Geert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin
Summer Feng, Rudy Gunawan, Chaitali Passey, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2019
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Dan Lu, Chunze Li, Matthew Riggs, et al.
British Journal of Clinical Pharmacology
|
July 23, 2017
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
Ophelia Yin, Hamim Zahir, Jonathan French, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2017
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Chunze Li, Bei Wang, Shang-Chiung Chen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Journal of Pharmacokinetics and Pharmacodynamics
|
July 24, 2012
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
James A Rogers, Daniel Polhamus, William R Gillespie, et al.
BMJ Open
|
March 8, 2013
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
Jorge Luiz Gross, James Rogers, Daniel Polhamus, et al.
Expert Review of Clinical Pharmacology
|
March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis
Geert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin
Summer Feng, Rudy Gunawan, Chaitali Passey, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2019
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Dan Lu, Chunze Li, Matthew Riggs, et al.
British Journal of Clinical Pharmacology
|
July 23, 2017
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
Ophelia Yin, Hamim Zahir, Jonathan French, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2017
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Chunze Li, Bei Wang, Shang-Chiung Chen, et al.
Page
of 1